NCT01241435

A Study of LY2216684 in Participants With Impaired Hepatic Function

The Effect of Impaired Hepatic Function on the Pharmacokinetics of LY2216684

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The duration of participation in this study is approximately 12 days, not including the screening visit. This study requires 1 clinic confinement of 5 days/4 nights followed by 1 out-patient follow-up visit. A screening visit is required within 30 days prior to the start of the study. This research study will be an open-label study. The study involves a single oral dose of 18 milligrams (mg) LY2216684 given as 2 tablets.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	LY2216684	Administered orally

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2010-11-16
• Last updated: 2018-10-22
• Results posted: 2018-10-22

Locations

3 sites across 1 country: United States